Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:10/1/2013

SAN DIEGO, Oct. 1, 2013 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has modified its prime contract and simultaneously exercised an option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the prime contract and increases the funding to support the development of a next generation rPA-based anthrax vaccine based on rPA produced in its platform technology, Pfēnex Expression Technology™.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised. During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPAThe exercise of this option allows for the completion of preclinical studies, implementation of analytical methods and cGMP manufacturing.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option and increase in funding by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.  
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare need
'/>"/>

SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Nuisance seaweed found to produce compounds with biomedical potential
2. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
3. UMass Medical School scientist named 2012 Pew Latin-American Fellow in the Biomedical Sciences
4. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
5. Top young Latin-American scientists named Pew Biomedical Fellows
6. Saladax Biomedical Enters into Master Collaboration Agreement with Bristol-Myers Squibb
7. BGI Tech and BAB jointly develop transgenic mice platform for biomedical research
8. Reproducibility Initiative to increase the value of biomedical research
9. £30 million boost for biomedical engineering research
10. MU celebrates $5 million partnership for advancing biomedical discoveries
11. CNIO participates in the ENCODE project: A stride forward in biomedical research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Ill. Scientists have scoured cow rumens and termite ... cell walls for the production of next-generation biofuels, but ... in the human lower intestine, researchers report. , Their ... the National Academy of Sciences , is the first ... microbes in the human gut can digest fiber, breaking ...
(Date:9/23/2014)... majority of drugs used to treat asthma today are the ... are urgently needed to treat this chronic respiratory disease, which ... to wheeze, cough, and find it difficult at best to ... is tough: asthma is a patient-specific disease, so what works ... animal models traditionally used to test new drug candidates often ...
(Date:9/23/2014)... SPRINGS, Florida , September 23, 2014 ... for innovative companies in tech sector position for significant investor ... products & services.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Mobileye N.V. (NYSE: MBLY ... Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Airway muscle-on-a-chip mimics asthma 2Airway muscle-on-a-chip mimics asthma 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7
... requires the same protein molecule that neurons need to ... to new research from the University of Illinois at ... the online journal PLOS ONE . , The ... cells into neurons and the process whereby cancer cells ...
... -- Critical to the recovery efforts following the devastating effects ... ability to assess damage within the reactor,s core. A study ... of scientists from Los Alamos National Laboratory (LANL) shows that ... to the reactor cores and locating the melted fuel. ...
... beverages containing toxins believed to pose potential risks to developing ... in Riverside and San Diego, suggesting that health care providers ... of hidden toxins in the food supply. In a ... Journal "Consumption habits of pregnant women and implications ...
Cached Biology News:Protein involved in nerve-cell migration implicated in spread of brain cancer 2Getting to the core of Fukushima 2Diets of pregnant women contain harmful, hidden toxins 2Diets of pregnant women contain harmful, hidden toxins 3Diets of pregnant women contain harmful, hidden toxins 4
(Date:9/23/2014)... 23, 2014 Proove Biosciences , ... industry leading research and data on the association between ... American Academy of Pain Management’ s 25th ... Arizona at the , Proove Biosciences ... and genetic predisposition to opioid misuse risk in chronic ...
(Date:9/23/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... pleased to announce that its wholly owned subsidiary, ... consultants to its team for further development of ... proprietary cell permeable peptide platform technology derived from ... the eye. Ms. Holly ...
(Date:9/23/2014)... Austin, TX (PRWEB) September 23, 2014 ... newest fertility clinic in South Austin, expanding a Central ... Austin and San Antonio. The satellite office for the ... and andrology options to the South Austin, Buda, Kyle ... bring effective and affordable fertility treatment directly to individuals ...
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... Zemea® propanediol, has been independently evaluated by NSF International and now ... Protection Agency (EPA) Design for the Environment (DfE) screen. Zemea® ... Products joint venture. , ... Loudon, TN (Vocus) December ...
... MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM ... an oncology company that identifies, develops and ... announced that it has received clearance from ... II, double-blind, randomized trials for nimotuzumab, its ...
... Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced today ... update on the progress of Sangamo,s ZFP Therapeutic,development programs ... pm (PT) on Monday, January 12, 2009 at the ... The presentation will be webcast live and ...
Cached Biology Technology:Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 2Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference 2
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: